Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Andreas Maderna

Showing results (11-20 of 21) with videos related to

Pageof 3
Sort By:
Journal of Chemical Information and Modeling|May 1, 2023
Building Machine Learning Small Molecule Melting Points and Solubility Models Using CCDC Melting Points DatasetXiangwei Zhu, Valery R Polyakov, Krishna Bajjuri, et al.
Bioorganic & Medicinal Chemistry Letters|November 12, 2013
New cytotoxic benzosuberene analogs. Synthesis, molecular modeling and biological evaluationZecheng Chen, Andreas Maderna, Sai Chetan K Sukuru, et al.
Journal of the American Chemical Society|October 28, 2014
Synthesis, molecular editing, and biological assessment of the potent cytotoxin leiodermatolideDamien Mailhol, Jens Willwacher, Nina Kausch-Busies, et al.
Cancer Research|August 27, 2009
RDEA119/BAY 869766: a potent, selective, allosteric inhibitor of MEK1/2 for the treatment of cancerCory Iverson, Gary Larson, Chon Lai, et al.
Bioorganic & Medicinal Chemistry Letters|August 29, 2006
Identification of isothiazole-4-carboxamidines derivatives as a novel class of allosteric MEK1 inhibitorsHassan El Abdellaoui, Chamakura V N S Varaprasad, Dinesh Barawkar, et al.
Bioorganic & Medicinal Chemistry Letters|October 1, 2011
Imidazo[1,5-a]quinoxalines as irreversible BTK inhibitors for the treatment of rheumatoid arthritisKyung-Hee Kim, Andreas Maderna, Mark E Schnute, et al.
Molecular Cancer Therapeutics|June 20, 2015
Novel Anti-TM4SF1 Antibody-Drug Conjugates with Activity against Tumor Cells and Tumor VasculatureAlberto Visintin, Kelly Knowlton, Edyta Tyminski, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 5, 2020
Development of Highly Optimized Antibody-Drug Conjugates against CD33 and CD123 for Acute Myeloid LeukemiaYoon-Chi Han, Jennifer Kahler, Nicole Piché-Nicholas, et al.
Journal of Medicinal Chemistry|November 29, 2014
Discovery of cytotoxic dolastatin 10 analogues with N-terminal modificationsAndreas Maderna, Matthew Doroski, Chakrapani Subramanyam, et al.
Cell Reports. Medicine|June 7, 2021
NOTCH3-targeted antibody drug conjugates regress tumors by inducing apoptosis in receptor cells and through transendocytosis into ligand cellsKenneth G Geles, Yijie Gao, Andreas Giannakou, et al.
Pageof 3

Showing results (11-20 of 21) with videos related to

Sort By:
Pageof 3
Journal of Chemical Information and Modeling|May 1, 2023
Building Machine Learning Small Molecule Melting Points and Solubility Models Using CCDC Melting Points DatasetXiangwei Zhu, Valery R Polyakov, Krishna Bajjuri, et al.
Bioorganic & Medicinal Chemistry Letters|November 12, 2013
New cytotoxic benzosuberene analogs. Synthesis, molecular modeling and biological evaluationZecheng Chen, Andreas Maderna, Sai Chetan K Sukuru, et al.
Journal of the American Chemical Society|October 28, 2014
Synthesis, molecular editing, and biological assessment of the potent cytotoxin leiodermatolideDamien Mailhol, Jens Willwacher, Nina Kausch-Busies, et al.
Cancer Research|August 27, 2009
RDEA119/BAY 869766: a potent, selective, allosteric inhibitor of MEK1/2 for the treatment of cancerCory Iverson, Gary Larson, Chon Lai, et al.
Bioorganic & Medicinal Chemistry Letters|August 29, 2006
Identification of isothiazole-4-carboxamidines derivatives as a novel class of allosteric MEK1 inhibitorsHassan El Abdellaoui, Chamakura V N S Varaprasad, Dinesh Barawkar, et al.
Bioorganic & Medicinal Chemistry Letters|October 1, 2011
Imidazo[1,5-a]quinoxalines as irreversible BTK inhibitors for the treatment of rheumatoid arthritisKyung-Hee Kim, Andreas Maderna, Mark E Schnute, et al.
Molecular Cancer Therapeutics|June 20, 2015
Novel Anti-TM4SF1 Antibody-Drug Conjugates with Activity against Tumor Cells and Tumor VasculatureAlberto Visintin, Kelly Knowlton, Edyta Tyminski, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 5, 2020
Development of Highly Optimized Antibody-Drug Conjugates against CD33 and CD123 for Acute Myeloid LeukemiaYoon-Chi Han, Jennifer Kahler, Nicole Piché-Nicholas, et al.
Journal of Medicinal Chemistry|November 29, 2014
Discovery of cytotoxic dolastatin 10 analogues with N-terminal modificationsAndreas Maderna, Matthew Doroski, Chakrapani Subramanyam, et al.
Cell Reports. Medicine|June 7, 2021
NOTCH3-targeted antibody drug conjugates regress tumors by inducing apoptosis in receptor cells and through transendocytosis into ligand cellsKenneth G Geles, Yijie Gao, Andreas Giannakou, et al.
Pageof 3